Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 15 recruiting now full pipeline

Kidney Diseases: full-pipeline trial registry

15 of 39 indexed Kidney Diseases trials are currently recruiting.

Corpus placement: #382 of 28,707 conditions by registered trial count.

39 US clinical trials · 15 currently recruiting · #382 of 28,707 conditions by registered trial count

Kidney Diseases: 39 US clinical trials tracked, 15 recruiting.

Kidney Diseases is the subject of 39 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Northwestern University, running 2 of these trials.

Enrollment posture brief

Registry condition kidney-diseases

OPEN 15 | RECR 38% | LATE 6 | EARLY 7 | RANK #382 | SPON 2

Nearest open-share peer: Anaplastic Oligodendroglioma (38% recruiting · 13 trials)

Lung Carcinoma53.8%B-cell Lymphoma46.2%Binge-Eating Disorder43.6%Kidney Diseases (this)38%Acute Myelogenous Leukemia17.9%
Open-enrollment share among volume-matched conditions near Kidney Diseases

Kidney Diseases lists 15 open slots (38% of 39 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Kidney Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Kidney Diseases recruits in line with its size-band peers.

    15 of 39 indexed trials (38.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Kidney Diseases trials is spread across many organizations.

    Northwestern University accounts for 2 of 39 trials (5.1%). 37 distinct sponsors appear on at least one study for this condition label.

  3. Typical Kidney Diseases enrolment sits around 126 participants.

    Median target enrolment is 126 among the 39 trials that report a genuine target (sentinel values excluded). 17 of those (43.6%) plan for fewer than 100 participants.

  4. Kidney Diseases splits between interventional and observational designs.

    26 interventional and 13 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 23Phase 35Phase 41

Open and recent trials

39 total, page 1 of 1

RECRUITING 50,000 participants

Rutgers University Study of the Genetics of Kidney Disease

Rutgers, The State University of New Jersey

NCT07217535

RECRUITING 5,000 participants

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Wake Forest University Health Sciences

NCT03615235

RECRUITING 2,000 participants

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

The Rogosin Institute

NCT01802034

RECRUITING 1,250 participants

The Effects of the CF Carrier State on the Kidneys and Pancreas

Philip Polgreen

NCT05474417

RECRUITING NA 600 participants

Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease

Emory University

NCT06693661

RECRUITING Phase 3 360 participants

Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

University of California, San Francisco

NCT06798909

RECRUITING 240 participants

Donor Outcomes Following Hand-Assisted and Robotic Living Donor Nephrectomy: a Retrospective Review

Methodist Health System

NCT04182607

RECRUITING Phase 3 220 participants

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Novartis Pharmaceuticals

NCT06858319

RECRUITING 200 participants

Transformative Research in Diabetic Nephropathy 2.0

University of Pennsylvania

NCT07444203

RECRUITING NA 150 participants

Evaluate the Impact of Targeted Physical Activity on Clinically Debilitated Dialysis Patients.

University of Illinois at Chicago

NCT06374537

RECRUITING NA 126 participants

Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure

Northwestern University

NCT05100017

RECRUITING 125 participants

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

Wake Forest University Health Sciences

NCT04752293

RECRUITING NA 120 participants

Dietary Intervention to Improve Kidney Transplant Outcomes

University of California, Davis

NCT05449496

RECRUITING Phase 1 60 participants

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Northwestern University

NCT05719714

RECRUITING NA 20 participants

Supporting VETerans With Kidney Disease Through Food As Medicine

VA Eastern Colorado Health Care System

NCT07194733

ACTIVE NOT RECRUITING NA 775 participants

Expanding Live Donor Kidney Transplantation Through Advocacy Training and Social Media

Johns Hopkins University

NCT03099434

ACTIVE NOT RECRUITING 600 participants

BRINK (BRain In Kidney Disease) Memory Study 2.0

Anne Murray

NCT04975464

ACTIVE NOT RECRUITING NA 376 participants

Access to Kidney Transplantation in Minority Populations

University of New Mexi

NCT04615819

ACTIVE NOT RECRUITING NA 347 participants

Promoting Increases in Living Donation Via Tele-navigation (PILOT)

University of Alabama at Birmingham

NCT05468463

ACTIVE NOT RECRUITING Phase 3 75 participants

Long Term Extension Study in Patients With Primary Hyperoxaluria

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

NCT04042402

ACTIVE NOT RECRUITING Phase 3 60 participants

Savolitinib vs. Sunitinib in MET-driven PRCC.

AstraZeneca

NCT03091192

ACTIVE NOT RECRUITING NA 20 participants

Prospective Feasibility Study Evaluating EchoMark LP Placement and EchoSure Measurements for Subjects Requiring Arteriovenous Fistulae

Sonavex

NCT04896476

COMPLETED 3,402 participants

Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19

University of Michigan

NCT04706533

COMPLETED 628 participants

Evaluation of the Analytical Performance of ALLEGRO™ Instrument

Nova Biomedical

NCT04096313

COMPLETED Phase 2 200 participants

A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures

Children's Mercy Hospital Kansas City

NCT00142064

COMPLETED Phase 4 165 participants

The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients

Mayo Clinic

NCT00275535

COMPLETED Phase 3 149 participants

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

MediBeacon

NCT05777174

COMPLETED Phase 2 97 participants

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02741323

COMPLETED Phase 2 84 participants

Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease

Shire

NCT00234702

COMPLETED NA 80 participants

Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease

Northwell Health

NCT03383627

COMPLETED 62 participants

BVA-200 vs BVA-100 Validation Study

Daxor Corporation

NCT06227819

COMPLETED NA 47 participants

Measurement of Renal Functional Reserve

Brigham and Women's Hospital

NCT03190070

COMPLETED NA 46 participants

Intermittent Pneumatic Compression Device for Vein Dilation in Kidney Disease Patients to Enable AVF Creation (FACT)

University of Chicago

NCT04063787

COMPLETED Phase 1 45 participants

A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

Cumberland Pharmaceuticals

NCT01238796

COMPLETED Phase 1 39 participants

First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes

Goldfinch Bio

NCT04880291

COMPLETED 32 participants

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™

FAST BioMedical

NCT03095391

COMPLETED 22 participants

Effect of Hormone Therapy on Renal Function

University of Colorado, Denver

NCT04482920

COMPLETED NA 18 participants

Standard vs Mini-PCNL for the Treatment of Stone Disease

The Cleveland Clinic

NCT04069013

COMPLETED Phase 1 10 participants

A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction

National Cancer Institute (NCI)

NCT00001298

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 3
Phase 3 5
Phase 4 1

Named interventions

Most-linked intervention names on Kidney Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR) Device
1 trials
Iohexol Device
1 trials
VFI Device
1 trials
carboxypeptidase-G2 Drug
1 trials
PCNL Procedure
1 trials
Iohexol infusion Diagnostic test
1 trials
p-aminohippurate clearance study Diagnostic test
1 trials

US sites by state

Facility locations filed on Kidney Diseases trials. A trial with sites in several states counts in each.

Illinois 8 trials
New York 7 trials
California 7 trials
Tennessee 6 trials
Texas 5 trials
Minnesota 5 trials
Georgia 5 trials
Florida 5 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Kidney Diseases page

39 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Kidney Diseases condition card totals 39 registered trials; most-linked intervention Placebo; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.